|View printer-friendly version|
|November 06, 2007 2:13 p.m.|
|First Patient Undergoes Expanded Cord Blood Transplant in the ExCell Registration Study of StemEx® for Leukemia and Lymphoma|
Patients are now being enrolled in the U.S. for the Gamida Cell-Teva Joint Venture ExCell trial studying StemEx® as an alternative treatment for bone marrow transplants.
Jerusalem, Israel, November 6, 2007 - Gamida Cell-Teva Joint Venture announced today that the first patient in the international, pivotal registration ExCell study has undergone a StemEx® transplant at the Ireland Cancer Center of University Hospitals Case Medical Center. StemEx® is a graft of expanded stem/progenitor cells, derived from a single unit of umbilical cord blood and transplanted in combination with non expanded cells from the same unit.